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Previous reports have shown that some ovarian endometrioid adenocarcinomas and ovarian clear cell 
adenocarcinomas derive from ovarian endometriosis (OE),  and that endocervical-like mucinous bor-
derline ovarian tumors are associated with OE.  We examined the relationship between the staging and 
histological subtypes of OE or epithelial ovarian tumors (EOT) and the serum levels of carbohydrate 
antigen 19-9 (CA19-9) and carbohydrate antigen 125 (CA125) to evaluate the potential of these markers 
for preoperative diagnosis.  First,  we analyzed the preoperative serum levels of CA19-9 and CA125 in 
195 patients who were histopathologically diagnosed with OE or EOT.  We then performed a case-
control study in which 308 women were enrolled,  the 195 women described above and 113 healthy 
women as control subjects.  Serum CA19-9 and CA125 levels were found to be useful in diﬀerentiating 
between OE and serous adenocarcinoma,  but not between OE and other EOT.  Moreover,  serum 
CA19-9 levels were useful for preoperative assessment between OE and stage I mucinous borderline 
ovarian tumors,  with or without the interstitial inﬁltration.  In addition,  considering that the serum 
CA19-9 levels in stage I mucinous borderline ovarian tumors were elevated via the interstitial inﬁltra-
tion of leukocytes and that precancerous lesions are associated with a cancerous glycosylation disor-
der in the process of inﬂammatory carcinogenesis,  the CA19-9 level may be considered a suitable 
biomarker for estimating drug susceptibility.
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he histological type and stage of tumors that 
were surgically resected by using laparotomy or 
laparoscopy are important prognostic factors in the 
deﬁnitive diagnosis of ovarian tumors [1-5].  For 
preoperative diagnosis,  a range of tools are used,  
including inquiry,  internal examination,  various imag-
ing modalities,  and supplementary tests such as with 
tumor markers.  The diagnostic accuracy of imaging 
modalities for malignant tumors (MT) is reported to 
vary within the range of 82-93ｵ [6,  7].  To deter-
mine the appropriate operative procedure,  diﬀerential 
diagnosis between benign and malignant tumors is 
conducted through histological examination,  along with 
the aid of tumor markers such as carbohydrate anti-
gen 125 (CA125) [8].  CA125,  a representative tumor 
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marker of ovarian cancer,  is one of the markers used 
to evaluate the eﬀectiveness of drug therapies [9].  
However,  elevated CA125 levels are not always 
observed in patients with ovarian clear cell adenocar-
cinoma (CCA) and ovarian mucinous adenocarcinoma 
(MA),  or in patients with other epithelial ovarian 
cancers [10,  11].  Moreover,  CA125 levels are aﬀected 
by menstruation and pregnancy,  since this antigen is 
produced by epithelial cells of the peritoneum,  pleura,  
and endometrium,  and are elevated in patients with 
ovarian endometriosis (OE) and pelvic inﬂammatory 
diseases [12].
　 Carbohydrate antigen 19-9 (CA19-9) levels are 
used as a diagnostic marker of gastrointestinal cancers 
such as pancreatic cancer and cholangiocarcinoma,  in 
which they exhibit a high positivity rate [13,  14].  
Even higher CA19-9 positivity rates have been reported 
in gynecological tumors such as MA,  ovarian endo-
metrioid adenocarcinoma,  and mucinous borderline 
ovarian tumors (MBT) [15,  16].  However,  elevated 
CA19-9 levels have also been reported in patients 
with benign tumors,  including OE and mature cystic 
teratoma,  and CA19-9 levels vary markedly among 
Lewis blood types in healthy individuals [17-20].  
Thus,  the application of these tumor markers for dif-
ferentiating ovarian cancer requires extreme caution.
　 Recent reports have shown that some ovarian 
endometrioid adenocarcinomas and CCA derive from 
OE,  and that endocervical-like mucinous borderline 
ovarian tumors (ELMBT) are associated with OE 
[21].  In Japan,  the incidences of CCA and ELMBT 
are signiﬁcantly higher than those in Europe and the 
United States [22-24].  Therefore,  we examined the 
relationship between the stage and histological subtype 
of OE or epithelial ovarian tumors (EOT) and the 
CA19-9 and CA125 levels in order to conﬁrm the 
usefulness of these antigens as preoperative diagnostic 
markers.
Materials and Methods
　 Subjects. The study subjects included 195 
patients who were histopathologically diagnosed with 
OE or EOT at the Kurashiki Central Hospital from 
January 2008 to December 2012.  The serum CA19-9 
and CA125 levels of the subjects were measured as a 
preoperative test.  Patients with ruptured ovarian 
tumors were excluded because they showed marked 
increases in CA19-9 and CA125 levels [25].  The 
International Federation of Gynecology and Obstetrics 
(FIGO) stage and World Health Organization histo-
logical classiﬁcations were utilized in the tumor stag-
ing [26,  27].  Ovarian tumors were classiﬁed into 8 
histological subtypes,  namely,  OE,  serous cystade-
noma,  mucinous cystadenoma,  ELMBT,  intestinal 
type mucinous borderline ovarian tumor (ITMBT),  
serous adenocarcinoma (SA),  MA,  and CCA.  The SA 
cases were all high-grade serous adenocarcinomas.  
The FIGO stages were classiﬁed into 4 categories,  
namely I,  II,  III,  and IV.  Interstitial inﬁltration of 
cancer cells and leukocytes in stage I ovarian tumors 
were categorized as present or absent.  As healthy 
controls,  113 healthy women who showed no abnor-
malities in liver function,  renal function,  glycolipid 
metabolism,  or abdominal and transvaginal ultra-
sonography upon medical examination were selected 
and requested to undergo measurements of serum 
CA19-9 and CA125 levels in the Comprehensive 
Health Center of our hospital.  The institutional 
review board approved this case-control study (No.  
1062).
　 Measurement of serum CA19-9 and CA125 
levels. Serum CA19-9 and CA125 levels were 
measured by using ARCHITECT i 2000 with special 
reagents,  ARCHITECT CA19-9 XR and CA125 II 
(Abbott Laboratories,  Abbott Park,  IL,  USA).  All 
serum samples were assayed within 2h after centrifu-
gation,  following the manufacturerʼs instructions.  
Because the CA19-9 levels of Lewis (a-b-) patients 
have been reported to be＜1.1U/ml [28],  we excluded 
subjects with serum CA19-9 levels＜1.1U/ml.
　 Statistical analysis. Data are expressed as the 
median values with range.  Statistical analysis was 
performed by using EZR Ver. 1.25 (Saitama Medical 
Center,  Jichi Medical University,  Saitama,  Japan) 
[29].  Comparisons between the 2 groups were per-
formed by using the Mann-Whitney U test.  For com-
parisons involving multiple groups,  the Kruskal-Wallis 
test was used with post hoc comparisons according to 
the Steel-Dwass method.  The chi-squared test was 
used to compare positive rates between the groups,  
and Fisherʼs exact test was used when the number of 
samples was small.  The multiple comparison test was 
done with Bonferroni correction.  Statistical signiﬁ-
cance was deﬁned as p＜0.05.  Only signiﬁcant p-val-
ues are given in the Tables.  CA19-9 and CA125 
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cutoﬀ values of 37.0 and 35U/ml,  respectively,  were 
assumed in this study.
Results
　 Patient characteristics. The number of 
patients,  patient age,  FIGO stage,  histological sub-
type of the ovarian tumors,  and characteristics of the 
healthy controls are shown in Table 1.  Ages were 
expressed as the median with range.  Interstitial inﬁl-
tration of stage I ovarian tumors was classiﬁed as 
present or absent.
　 Serum CA19-9 and CA125 levels in the 
healthy controls and patients according to the 
histological subtype of the ovarian tumors.
Serum CA19-9 and CA125 levels in the healthy con-
trols and the patients according to the histological 
subtype of the ovarian tumors are shown in Table 2.  
Serum CA19-9 levels (median,  range U/ml) were 
signiﬁcantly higher in the patients with OE (36.8,  
2.7-471.8),  MBT (24.6,  6.1-6,222.3),  and MT (18.5,  
1.1-14,417.0) than in the healthy controls (8.0,  1.4-
31.7).  Moreover,  serum CA19-9 levels were signiﬁ-
cantly lower in the patients with serous cystadenoma 
(7.7,  2.0-31.4),  mucinous cystadenoma (11.9,  1.5-76.9),  
and SA (11.2,  1.1-1,102.9) than in the patients with 
OE.  For CA19-9,  the positivity rate in patients with 
OE (50ｵ) was signiﬁcantly higher than that in patients 
with SA (11ｵ),  but the positivity rates were not 
signiﬁcantly diﬀerent between patients with other 
histological subtypes and those with SA.  The positiv-
ity rates in serous cystadenoma (0ｵ) and mucinous 
cystadenoma (17ｵ) were signiﬁcantly lower than that 
in patients with OE.
　 Serum CA125 levels were signiﬁcantly higher in 
the patients with OE (51.0,  9-226),  MBT (41.0,  
7-1,630),  and MT (277.0,  9-22,470) than in the 
healthy controls (10.0,  5-32).  Serum CA125 levels 
were signiﬁcantly lower in the patients with OE,  
serous cystadenoma (14.0,  6-30),  mucinous cystade-
noma (15.0,  4-69),  ELMBT (47.0,  14-889),  ITMBT 
(31.0,  7-1,630),  MA (22.0,  9-114),  and CCA (46.0,  
11-2,899) than in the patients with SA (1,847.0,  
58-22,470).  For CA125,  the positivity rates of patients 
with OE (73ｵ),  serous cystadenoma (0ｵ),  mucinous 
cystadenoma (11ｵ),  ITMBT (47ｵ),  MA (40ｵ),  and 
CCA (57ｵ) were signiﬁcantly lower than that of 
patients with SA (100ｵ).  The positivity rates for 
serous cystadenoma and mucinous cystadenoma were 
signiﬁcantly lower than that for OE.
　 Serum CA19-9 and CA125 levels according 
to the histological subtypes and FIGO stage of 
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Table 1　 Patient characteristics
Age FIGO stage
Median I II III IV
n Median (range) Interstitial inﬁltration(absent,  present)
Healthy control 113 51.0 (32-68)
Ovarian endometriosis  52 34.0 (22-69)
Epithelial ovarian tumors
Benign tumor  68 52.0 (22-91)
　Serous cystadenoma  33 49.0 (24-91)
　Mucinous cystadenoma  35 55.0 (22-81)
Borderline tumor
　Mucinous borderline tumor  24 48.0 (25-82) 22 (17, 5 a) 1  0 1
　　Endocervical-like mucinous borderline tumor  7 42.0 (26-81) 6 (3, 3) 1  0 0
　　Intestinal type mucinous borderline tumor  17 50.0 (25-82) 16 (14, 2) 0  0 1
Malignant tumor  51 59.0 (20-86) 19 (0, 19 b) 2 27 3
　Serous adenocarcinoma  27 65.0 (38-80) 0 (0, 0) 1 23 3
　Mucinous adenocarcinoma  10 39.5 (20-86) 10 (0, 10) 0  0 0
　Clear cell adenocarcinoma  14 54.0 (34-74) 9 (0, 9) 1  4 0
a,  For the stage I mucinous borderline tumors,  interstitial inﬁltration was consisted of only leukocytes; b,  For the stage I malignant tumors,  
ilnterstitial inﬁltration was consisted of only cancer cells.
the ovarian tumors. Serum CA19-9 and CA125 
levels according to the histological subtypes and FIGO 
stages of the ovarian tumors are presented in Table 3.  
Most of the cases of ELMBT,  ITMBT,  MA,  and 
CCA were categorized as stage I or II,  early-stage 
cancers; and most of the cases of SA were catego-
rized as stage III or IV,  advanced cancers.
　 Serum CA19-9 levels were signiﬁcantly higher in 
the patients with OE (36.8,  2.7-471.8) than in the 
patients with stage III SA (16.3,  1.1-1,102.9).  Markedly 
elevated CA19-9 levels were observed in the patients 
with ELMBT,  which involved interstitial inﬁltration 
of leukocytes,  and in those with MA,  which involved 
interstitial inﬁltration of cancer cells.  For CA19-9,  
the positivity rate of stage III SA (16ｵ) was signiﬁ-
cantly lower than that of OE (50ｵ).
　 Serum CA125 levels were signiﬁcantly higher in 
the patients with stage III SA (2,073.0,  58-22,470) 
than in the patients with OE (51.0,  9-226).  Serum 
CA125 levels were signiﬁcantly lower in the patients 
with stage I ELMBT (43.5,  14-889),  stage I ITMBT 
(30.5,  7-200),  stage I MA (26.0,  9-114),  and stage I 
CCA (33.0,  11-119) than in the patients with stage III 
SA.  For CA125,  the positivity rate of OE (73ｵ) 
was signiﬁcantly lower than that of III SA (100ｵ).  
Moreover,  the positivity rates of stage III and IV 
EOT were 100ｵ of CA125.
　 Serum CA19-9 and CA125 levels according 
to interstitial inﬁltrates in the patients with 
stage I epithelial ovarian tumors and ovarian 
endometriosis. The serum CA19-9 and CA125 
levels according to interstitial inﬁltrates in the patients 
with stage I EOT and OE are shown in Table 4.  For 
stage I MBT,  the serum CA19-9 levels,  as well as 
the positivity rate of CA19-9,  were signiﬁcantly 
higher in the patients with interstitial inﬁltration of 
leukocytes (218.8,  39.1-3,303.3; 100ｵ) than in those 
with OE (36.8,  2.7-471.8; 50ｵ) and without intersti-
tial inﬁltration (14.2,  6.1-33.9; 0ｵ).  Serum CA19-9 
levels,  as well as the positivity rate with CA19-9,  
were signiﬁcantly lower in the patients with stage I 
MBT without interstitial inﬁltration of leukocytes 
than in the patients with OE.  In particular,  the posi-
tivity rate of stage I MBT with interstitial inﬁltration 
was 100ｵ of CA19-9.
　 In the patients with stage I MT with interstitial 
inﬁltration of cancer cells,  the serum CA19-9 levels,  
as well as the positivity rate of CA19-9,  did not dif-
fer signiﬁcantly from those in the patients with OE.  
However,  10 patients with stage I MT showed ele-
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Table 2　 Serum CA19-9 and CA125 levels in the healthy controls and patients according to the histological subtype of the ovarian 
tumors
Serum CA19-9 levels Serum CA125 levels
n Median (range) Positive rate (%) n Median (range) Positive rate (%)
Healthy control 100 8.0 (1.4-31.7) c,d,e 0 113 10.0 (5-32) c,d,e 0
Ovarian endometriosis  48 36.8 (2.7-471.8) a,b,d,f 50$  52 51.0 (9-226) a,b,d,g,j 73$
Epithelial ovarian tumors
Benign tumor  56 8.5 (1.5-76.9) c,e 9  68 14.0 (4-69) c,d,e 6
　Serous cystadenoma  27 7.7 (2.0-31.4) e 0#  33 14.0 (6-30) e,i,j,k,l 0#,$
　Mucinous cystadenoma  29 11.9 (1.5-76.9) e 17#  35 15.0 (4-69) e,g,j 11#,$
Borderline tumor
　Mucinous borderline tumor  20 24.6 (6.1-6,222.3) a,b 35  24 41.0 (7-1,630) a,b,d 54
　Endocervical-like mucinous borderline tumor  7 39.1 (11.5-4,533.2) 57  7 47.0 (14-889) j 71
　Intestinal type mucinous borderline tumor  13 16.0 (6.1-6,222.3) 23  17 31.0 (7-1,630) f,g,i,j 47$
Malignant tumor  49 18.5 (1.1-14,417.0) a,b,e 31  51 277.0 (9-2,2470) a,b,c,e 77
　Serous adenocarcinoma  27 11.2 (1.1-1,102.9) e 11#  27 1,847.0 (58-22,470) f,g,h,i,k,l 100#
　Mucinous adenocarcinoma  9 56.4 (2.5-14,417.0) 56  10 22.0 (9-114) f,j 40$
　Clear cell adenocarcinoma  13 39.0 (2.6-132.0) 54  14 46.0 (11-2,899) f,j 57$
Serum CA19-9 levels,  cut oﬀ value 37.0U/ml; serum CA125 levels,  cut oﬀ value 35U/ml
The Kruskal-Wallis test was used with post hoc comparsions according to the Steel-Dwass method.
a,  p＜0.05 vs.  healthy control; b,  p＜0.05 vs.  benign tumor; c,  p＜0.05 vs.  mucinous borderline tumor; d,  p＜0.05 vs.  malignant tumor; e,  p＜0.05 vs.  ovarian 
endometriosis; f,  p＜0.05 vs.  serous cystadenoma; g,  p＜0.05 vs.  mucinous cystadenoma; h,  p＜0.05 vs.  endocervical-like mucinous borderline tumor; i,  p＜
0.05 vs.  intestinal type mucinous borderline tumor; j,  p＜0.05 vs.  serous adenocarcinoma; k,  p＜0.05 vs.  mucinous adenocarcinoma; l,  p＜0.05 vs.  clear cell 
adenocarcinoma
The Chi-squared test or Fisherʼs exact test was used with Bonferroni correction for the comparison of positive rates.
#,  p＜0.05 vs.  ovarian endometriosis; $,  p＜0.05 vs.  serous adenocarcinoma.
vated CA19-9 levels higher than the cutoﬀ value,  and 
9 of the 10 had interstitial inﬁltration of cancer cells.
　 For stage I MBT,  the serum CA125 levels,  as well 
as the positivity rate with CA125,  were signiﬁcantly 
lower in the patients without interstitial inﬁltrate 
(30.0,  7-9; 41ｵ) than in the patients with OE (51.0,  
9-226; 73ｵ).
　 For stage I MT,  the serum CA125 levels,  as well 
as the positivity rate with CA125,  were signiﬁcantly 
lower in the patients with interstitial inﬁltrates (30.0,  
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Table 3　 Serum CA19-9 and CA125 levels according to the histological subtypes and FIGO stage of the ovarian tumors
A
Serum CA19-9 levels Positive rate (%) 
Median (range)
FIGO stage
n I II III IV
Ovarian endometriosis 48 50 (24/48)36.8 (2.7-471.8) b
Epithelial ovarian tumors
　Mucinous borderline tumor 20 28 (5/18)18.1 (6.1-3,303.3)
100 (1/1)
4,533.2 ―
100 (1/1)
6,222.3
　Endocervical-like
　　mucinous borderline tumor
 7 50 (3/6)35.8 (11.5-3,303.3)
100 (1/1)
4,533.2 ― ―
　Intestinal type
　　mucinous borderline tumor
13 17 (2/12)15.3 (6.1-524.9) ― ―
100 (1/1)
6,222.3
　Serous adenocarcinoma 27 ― 0 (0/1)20.6
12 (3/23) #
16.3 (1.1-1,102.9) a
0 (0/3)
8.3 (2.8-9.6)
　Mucinous adenocarcinoma  9 56 (5/9)56.4 (2.5-14,471.0) ― ― ―
　Clear cell adenocarcinoma 14 63 (5/8)41.7 (4.2-126.1)
0 (0/1)
11.9
50 (2/4)
67.8 (2.3-132.0)
B
Serum CA125 levels Positive rate (%)
Median (range)
FIGO stage
n I II III IV
Ovarian endometriosis 52 73 (38/52)51.0 (9-226) b
Epithelial ovarian tumors
　Mucinous borderline tumor 24 50 (11/22)35.5 (7-889) b
100 (1/1)
289.0 ―
100 (1/1)
1,630
　Endocervical-like
　　mucinous borderline tumor
 7 67 (4/6)43.5 (14-889) b
100 (1/1)
289.0 ― ―
　Intestinal type
　　mucinous borderline tumor
17 44 (7/16)30.5 (7-200) b ― ―
100 (1/1)
1,630
　Serous adenocarcinoma 27 ― 100 (1/1)86.0
100 (23/23) #
2,073.0  (58-22,470) a
100 (3/3)
1,515.0 (807-1,729)
　Mucinous adenocarcinoma 10 40 (4/10)26.0 (9-114) b ― ― ―
　Clear cell adenocarcinoma 14  44 (4/9)33.0 (11-119) b
0 (0/1)
29.0
100 (4/4)
379.5 (53-2,899)
(A) For serum CA19-9 levels,  cut oﬀ value 37.0U/ml.
(B) For serum CA125 levels,  cut oﬀ value 35U/ml.
The Kruskal-Wallis test was used with post hoc comparsions according to the Steel-Dwass method.
a,  p＜0.05 vs.  ovarian endometriosis; b,  p＜0.05 vs.  serous adenocarcinoma stage III
The Chi-squared test or Fisherʼs exact test was used with Bonferroni correction for the comparison of positive rates.
#,  p＜0.05 vs.  ovarian endometriosis.
9-119; 42ｵ) than in the patients with OE.
Discussion
　 In this study,  we examined the relationship between 
the FIGO stage and histological subtype of OE or 
EOT and the serum CA19-9 and CA125 levels to 
conﬁrm the usefulness of these antigens as preopera-
tive diagnostic markers.
　 According to the recent carcinogenesis model of the 
ovary,  ovarian cancer can be divided into types I and 
II using a new classiﬁcation based on morphological,  
molecular and biological analyses,  and each type of 
tumor shows a diﬀerent mode of progression in car-
cinogenesis [30,  31].  Low-grade serous,  mucinous,  
endometrioid,  clear cell,  and transitional cell carcino-
mas,  which are often conﬁned to the ovary at the time 
of diagnosis,  are classiﬁed as type I and considered to 
be genetically stable without TP53 mutations [32,  
33].  In contrast,  type II tumors,  including high-grade 
serous carcinomas,  undiﬀerentiated carcinomas,  and 
carcinosarcomas,  are more aggressive and genetically 
highly unstable [34-36].  Despite a relatively good 
prognosis in early-stage disease,  MA and CCA fre-
quently have poorer responses to chemotherapies and 
survival than serous ovarian cancers [37-39].  MBT,  
which are generally characterized as having low malig-
nant potential,  without interstitial inﬁltration of can-
cer cells,  present with peritoneal implants,  lymph 
node metastases,  and recurrence after resection [40-
42].
　 In the histological subtype classiﬁcation in our 
study,  the serum CA19-9 levels and positivity rate of 
CA19-9 were signiﬁcantly higher in patients with OE 
than SA,  but those of CA125 were signiﬁcantly lower 
in OE than in SA.  For CA125,  the positivity rates in 
subjects with OE,  serous cystadenoma,  mucinous 
cystadenoma,  ITMBT,  MA,  and CCA were signiﬁ-
cantly lower than that in subjects with SA.
　 Several studies have described the positive rates 
of ovarian cancer and OE by using CA19-9 and 
CA125 levels as diagnostic markers.  Kataoka et al.  
[15] reported that both CA19-9 and CA125 could be 
used to determine the histological type,  because dif-
ferent positivity rates of CA19-9 and CA125 were 
observed according to the histological types of ovarian 
cancer.  In other studies,  one half of patients with 
localized (stage I) ovarian cancer and 90ｵ of patients 
with advanced disease (stages II-IV) had increased 
serum CA125 levels [43].  For the revised American 
Society for Reproductive Medicine classiﬁcation of 
endometriosis,  the positivity rates of stage III and IV 
endometriosis were approximately 40ｵ and 60ｵ of 
CA19-9 and 50ｵ and 80ｵ of CA125,  respectively 
[44].
　 In the present study,  there were no signiﬁcant 
diﬀerences between the positivity rate of CA19-9 and 
that of CA125 in either ovarian cancer or OE.  The 
diﬀerence in the positivity rate of serum CA19-9 and 
CA125 among histological types of ovarian cancer was 
thought to depend on the diversity of histological types 
and the mechanism of production of these antigens in 
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Table 4　 Serum CA19-9 and CA125 levels according to interstitial inﬁltrates in the patients with stage I epithelial ovarian tumors and 
ovarian endometriosis
Serum CA19-9 levels
Positive rate (%)
Median (range)
Serum CA125 levels
Positive rate (%)
Median (range)
Interstitial inﬁltration Interstitial inﬁltration
n absent present n absenct present
Ovarian endometriosis 48
50 (24/48)
36.8 (2.7-471.8)
52
73 (38/52)
51.0 (9-226)
Mucinous borderline tumor
　FIGO stage I 18
0 (0/13) #
14.2 (6.1-33.9) a
100 (5/5) $
218.8 (39.1-3,303.3) a,b
22
41 (7/17) #
30.0 (7-95) a
80 (4/5)
90.0 (14-889)
Malignant tumor
　FIGO stage I 17
59 (10/17)
44.3 (2.5-14,417.0)
19
42 (8/19) #
30.0 (9-119) a
Serum CA19-9 levels,  cut oﬀ value 37.0U/ml; serum CA125 levels,  cut oﬀ value 35U/ml.
The Mann-Whitney U test or the  Kruskal-Walls test was used with post hoc comparsions according to the Steel-Dwass method.
a,  p＜0.05 vs.  ovarian endmetoriosis; b,  p＜0.05 vs.  intersititial inﬁltration absence.
The Chi-squared test or Fisherʼs exact test was used with Bonferroni correction for the comparison of positive rates.
#,  p＜0.05 vs.  ovarian endmetoriosis; $,  p＜0.05 vs.  intersititial inﬁltration absence.
type I and II ovarian cancer.  Serum CA19-9 and 
CA125 levels were suggested to depend on the subtype 
of MBT,  as well as the histological type of ovarian 
cancer.  The positivity rate and serum levels of CA125 
were signiﬁcantly higher in SA than in other ovarian 
cancers.
　 CA19-9,  the carbohydrate antigen sialyl Lewis a,  
is not a cancer-speciﬁc antigen,  but a diﬀerentiation 
antigen [45].  Furthermore,  epigenetic suppression of 
gene expression,  including DNA methylation and his-
tone deacetylation associated with carcinogenesis,  has 
previously been reported to be the underlying cause of 
the induction of sialyl Lewis a carbohydrate expres-
sion in early-stage cancers [46-49].  In addition,  
disialyl Lewis a carbohydrate,  which is highly expressed 
in normal epithelial cells,  serves as a speciﬁc carbo-
hydrate ligand of sialic acid-binding immunoglobulin-
like lectin-7,  and has been shown to mediate the 
interactions between leukocytes and epithelial cells in 
the normal mucosa [47].  Thus,  disialyl Lewis a car-
bohydrate is considered to play an important role in 
the maintenance of immunological homeostasis [47].
　 In this study,  for stage I MBT,  the serum CA19-9 
levels and positivity rate in the patients with intersti-
tial inﬁltration of leukocytes were signiﬁcantly higher 
than in those without interstitial inﬁltration and in 
those with OE.  Therefore,  the elevation of serum 
CA19-9 levels was considered to depend on the inter-
stitial inﬁltration of leukocytes in MBT.  In contrast,  
all the patients with stage I MT in this study had 
interstitial inﬁltration of cancer cells,  but there were 
no signiﬁcant diﬀerences in the serum levels of 
CA19-9 between stage I MT and OE,  or in the posi-
tivity rates of CA19-9.  Furthermore,  the patients 
with stage I MT in this study did not include any his-
tological types such as SA and endometrioid adenocar-
cinoma other than MA and CCA.  However,  10 
patients with stage I MT showed elevated CA19-9 
levels above the cutoﬀ value,  of whom 9 had intersti-
tial inﬁltration of cancer cells.  These elevated serum 
CA19-9 levels in MT were considered to be due to the 
diﬀerences in the degree of interstitial inﬁltration of 
cancer cells and histological type.  The mechanism of 
the elevation of CA19-9 levels in ovarian cysts has 
been well documented in a number of studies of mature 
cystic teratomas.  Ito et al.  [18] reported that leakage 
of CA19-9 from the cystic cavity into the bloodstream 
might be the main mechanism of elevation of the serum 
CA19-9 level.
　 Therefore,  the mechanism of the elevation of 
serum CA19-9 levels involves the leakage of CA19-9 
into the bloodstream from the cyst cavity via intersti-
tial inﬁltration.  CA19-9 levels are also elevated in 
patients with MBT with interstitial inﬁltration of 
leukocytes.  These phenomena suggest that abnormali-
ties in the expression of the carbohydrate moiety on 
the cell surface might be responsible for the carcino-
genesis process.  Therefore,  in the immediate future,  
there is need of genome-wide analyses of the histo-
logical types of various ovarian cancers.  With this 
information in hand,  the CA19-9 level could become 
a tool for estimating drug susceptibility and prognosis.
　 In conclusion,  serum CA19-9 and CA125 levels 
were useful in diﬀerentiating between OE and SA,  but 
not between OE and EOT.  Moreover,  serum CA19-9 
levels were useful for preoperative assessment between 
OE and stage I MBT,  with or without interstitial 
inﬁltration.  In addition,  considering that the serum 
CA19-9 levels in stage I MBT were elevated via the 
interstitial inﬁltration of leukocytes and that precan-
cerous lesions are associated with a cancerous glyco-
sylation disorder in the process of inﬂammatory car-
cinogenesis,  the CA19-9 level may be considered as a 
suitable biomarker for estimating drug susceptibility 
in the future.
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